Abstract:Drug resistance remains a major challenge in cancer treatment, necessitating the development of novel strategies to overcome it. Protein arginine methyltransferases (PRMTs) are enzymes responsible for epigenetic arginine methylation, which regulates various biological and pathological processes, as a result, they are attractive therapeutic targets for overcoming anti-cancer drug resistance. The ongoing development of small molecules targeting PRMTs has resulted in the generation of chemical probes for modulating most PRMTs and facilitated clinical treatment for the most advanced oncology targets, including PRMT1 and PRMT5. In this review, we summarize various mechanisms underlying protein arginine methylation and the roles of specific PRMTs in driving cancer drug resistance. Furthermore, we highlight the potential clinical implications of PRMT inhibitors in decreasing cancer drug resistance. PRMTs promote the formation and maintenance of drug-tolerant cells via several mechanisms, including altered drug efflux transporters, autophagy, DNA damage repair, cancer stem cell-related function, epithelial-mesenchymal transition, and disordered tumor microenvironment. Multiple preclinical and ongoing clinical trials have demonstrated that PRMT inhibitors, particularly PRMT5 inhibitors, can sensitize cancer cells to various anti-cancer drugs, including chemotherapeutic, targeted therapeutic, and immunotherapeutic agents. Combining PRMT inhibitors with existing anti-cancer strategies will be a promising approach for overcoming anti-cancer drug resistance. Furthermore, enhanced knowledge of the complex functions of arginine methylation and PRMTs in drug resistance will guide the future development of PRMT inhibitors and may help identify new clinical indications.

An updated patent review of protein arginine N-methyltransferase inhibitors (2019-2022)

A Patent Review of Arginine Methyltransferase Inhibitors (2010–2018)

A patent review of PRMT5 inhibitors to treat cancer (2018 - present)

Small Molecule Inhibitors of Protein Arginine Methyltransferases

Arginine Methyltransferase 5 (PRMT5) Inhibitors with 3-(1H-benzo[d]imidazol- 2-Yl)anilines Core Identified by Virtual Screening and Biological Evaluation.

Overview of PRMT1 modulators: Inhibitors and degraders

Medicinal chemistry insights into PRMT5 inhibitors

Pharmacophore-based virtual screening and biological evaluation of small molecule inhibitors for protein arginine methylation

Medicinal chemistry strategies targeting PRMT5 for cancer therapy.

The Development of Tetrazole Derivatives as Protein Arginine Methyltransferase I (PRMT I) Inhibitors

Protein arginine methylation: from enigmatic functions to therapeutic targeting

The Role of PRMT1 in Cellular Regulation and Disease: Insights into Biochemical Functions and Emerging Inhibitors for Cancer Therapy

Protein arginine methyltransferases: promising targets for cancer therapy

DNA methyltransferase inhibitors: an updated patent review (2012-2015)

Overview of the Development of Protein Arginine Methyltransferase Modulators: Achievements and Future Directions.

Overview of the PRMT6 modulators in cancer treatment: Current progress and emerged opportunity

Design, Synthesis and Biological Evaluation of Novel and Potent Protein Arginine Methyltransferases 5 Inhibitors for Cancer Therapy

PRMT1 in human neoplasm: cancer biology and potential therapeutic target

Virtual screening and biological evaluation of novel small molecular inhibitors against protein arginine methyltransferase 1 (PRMT1)

Promising role of protein arginine methyltransferases in overcoming anti-cancer drug resistance

Discovery of alkyl bis(oxy)dibenzimidamide derivatives as novel protein arginine methyltransferase 1 (PRMT1) inhibitors